Consuming olive oil may reduce mortality risk in U.S. adults
Jan 12, 2022
Replacing butter, margarine, mayonnaise and dairy fat with olive oil is linked to reductions in total, cause-specific mortality.
Sugar-sweetened drink intake linked to mortality from some cancers
Sep 19, 2022
Sugar-sweetened beverages were associated with increased mortality for colorectal and kidney cancers, even after adjustment for body mass index.
Premature acute myocardial infarction mortality declined from 1999 to 2019
Dec 23, 2021
The decline has slowed since 2011; it was higher among large and medium/small metros versus rural counties.
Adverse effects generally mild after BNT162b2 mRNA booster in over 60s
Apr 18, 2022
Thirty percent of those aged 60 years or older receiving a booster reported at least one adverse event; few sought medical attention.
Global prevalence of young-onset dementia examined
Jul 20, 2021
Worldwide, an estimated 3.9 million people aged 30 to 64 years are living with young-onset dementia.
Disparities in COVID-19 vaccination identified among healthcare employees
Jun 16, 2021
Vaccination was least likely among clinical nurses, support staff and workers at skilled nursing and rehabilitation facilities.
CDC estimates U.S. COVID-19 infections now close to 140 million
Mar 02, 2022
The new findings are from the CDC national antibody seroprevalence survey of antibodies to the coronavirus triggered by infection, not by vaccination.
Preventive aspirin use up for seniors with versus without diabetes
Jun 22, 2021
Among those with diabetes, the likelihood of using aspirin did not differ for older versus younger (60 to 69 years) age categories.
Pfizer-BioNTech COVID-19 vaccine receives full FDA approval
Aug 23, 2021
The vaccine will now be marketed as Comirnaty and is fully approved for the prevention of COVID-19 in individuals 16 years and older.
Thrombosis, thrombocytopenia syndrome up after Ad26.COV2.S
Jan 28, 2022
Rates of 3.83 per million vaccine doses for Ad26.COV2.S (Johnson & Johnson) have been reported, versus 0.00855 per million for mRNA-based vaccines such as Pfizer-BioNTech and Moderna.